US Stock MarketDetailed Quotes

MRK Merck & Co

Watchlist
  • 101.880
  • -0.440-0.43%
Close Nov 1 16:00 ET
  • 101.880
  • 0.0000.00%
Post 20:01 ET
258.25BMarket Cap21.31P/E (TTM)

Merck & Co Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
52.19%5.64B
130.77%3.09B
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
45.52%19.1B
-13.05%4.43B
16.78%5.6B
Net income from continuing operations
191.44%5.46B
68.74%4.77B
-97.40%377M
-140.62%-1.23B
46.06%4.75B
-251.23%-5.97B
-34.41%2.83B
17.54%14.53B
-21.08%3.02B
-28.86%3.25B
Operating gains losses
-132.39%-57M
68.22%-143M
-123.96%-340M
-272.41%-100M
-90.81%34M
-37.81%176M
-163.56%-450M
173.14%1.42B
114.32%58M
154.33%370M
Depreciation and amortization
25.36%1.13B
-0.71%984M
-0.95%3.87B
8.07%964M
5.74%1.01B
-3.73%903M
-11.52%991M
21.62%3.91B
6.83%892M
26.35%959M
Deferred tax
49.01%-181M
81.59%-51M
-21.11%-1.9B
-203.26%-931M
49.17%-336M
-35.50%-355M
18.05%-277M
-938.50%-1.57B
-293.08%-307M
-66,000.00%-661M
Other non cash items
-99.13%91M
-25.73%739M
804.23%11.76B
240.15%449M
-126.76%-99M
1,488.26%10.42B
595.80%995M
-44.90%1.3B
-56.86%132M
116.37%370M
Change In working capital
38.14%-1.01B
-17.02%-3.38B
20.74%-2.21B
141.50%144M
727.76%2.18B
-16.94%-1.64B
-122.48%-2.89B
27.53%-2.78B
-671.11%-347M
289.21%263M
-Change in receivables
----
----
-78.26%-1.15B
----
----
----
----
68.32%-644M
----
----
-Change in inventory
----
----
-406.83%-816M
----
----
----
----
76.11%-161M
----
----
-Change in payables and accrued expense
----
----
3,843.90%1.62B
----
----
----
----
-71.13%41M
----
----
-Change in other current liabilities
----
----
183.67%456M
----
----
----
----
-212.60%-545M
----
----
-Change in other working capital
----
----
-57.09%-2.31B
----
----
----
----
16.21%-1.47B
----
----
Cash from discontinued investing activities
0
0
Operating cash flow
52.19%5.64B
130.77%3.09B
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
35.34%19.1B
-11.95%4.43B
16.78%5.6B
Investing cash flow
Cash flow from continuing investing activities
90.66%-1.07B
41.67%-1.38B
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
69.79%-4.96B
85.49%-1.75B
9.33%-962M
Capital expenditure reported
18.03%-791M
14.50%-861M
11.96%-3.86B
13.93%-989M
19.89%-902M
14.53%-965M
-2.34%-1.01B
1.35%-4.39B
4.88%-1.15B
3.92%-1.13B
Net business purchase and sale
--0
43.78%-746M
-9,843.80%-12.03B
--0
--0
---10.71B
---1.33B
99.06%-121M
--0
-12,200.00%-121M
Net investment purchase and sale
-95.77%11M
495.16%245M
482.61%1.85B
320.54%1.06B
77.88%587M
550.00%260M
83.29%-62M
-147.12%-483M
-191.12%-482M
197.30%330M
Net other investing changes
-775.76%-289M
-137.84%-14M
-212.50%-36M
82.05%-21M
57.78%-19M
-375.00%-33M
-79.67%37M
135.16%32M
-10.38%-117M
-4,400.00%-45M
Cash from discontinued investing activities
Investing cash flow
90.66%-1.07B
41.67%-1.38B
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
70.04%-4.96B
85.49%-1.75B
9.33%-962M
Financing cash flow
Cash flow from continuing financing activities
-67.64%1.22B
-37.00%-2.81B
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-394.45%-9.12B
-129.84%-1.55B
-18.82%-2.7B
Net issuance payments of debt
-41.30%3.6B
-75,000.00%-751M
285.87%4.18B
-200.00%-3M
-94.50%-1.95B
--6.13B
99.92%-1M
-238.01%-2.25B
-100.01%-1M
---1B
Net common stock issuance
25.74%-251M
18.12%-122M
---1.35B
---393M
---466M
---338M
---149M
--0
--0
--0
Cash dividends paid
-5.36%-1.99B
-5.23%-1.95B
-6.18%-7.45B
-5.83%-1.85B
-6.18%-1.86B
-6.50%-1.89B
-6.19%-1.85B
-6.08%-7.01B
-6.51%-1.75B
-5.94%-1.75B
Proceeds from stock option exercised by employees
-10.98%73M
190.00%87M
-67.45%125M
-97.74%6M
-30.00%7M
-15.46%82M
150.00%30M
90.10%384M
97.76%265M
-41.18%10M
Net other financing activities
5.98%-220M
3.70%-78M
-36.67%-328M
95.59%-3M
-128.57%-10M
-125.00%-234M
21.36%-81M
-102.75%-240M
-106.06%-68M
159.32%35M
Cash from discontinued financing activities
0
0
Financing cash flow
-67.64%1.22B
-37.00%-2.81B
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-451.68%-9.12B
-129.84%-1.55B
-18.82%-2.7B
Net cash flow
Beginning cash position
-42.05%5.67B
-45.91%6.91B
56.40%12.77B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
0.17%8.17B
12.27%11.28B
13.01%9.75B
Current changes in cash
245.29%5.78B
64.22%-1.1B
-217.36%-5.89B
-272.52%-1.95B
60.68%3.11B
-374.93%-3.98B
-712.35%-3.07B
3,312.24%5.02B
162.29%1.13B
32.56%1.94B
Effect of exchange rate changes
11.83%-82M
-258.62%-138M
105.61%23M
-49.18%186M
61.89%-157M
69.90%-93M
258.18%87M
-208.27%-410M
638.24%366M
-795.65%-412M
End cash Position
99.11%11.37B
-42.05%5.67B
-45.91%6.91B
-45.91%6.91B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
56.40%12.77B
12.27%11.28B
Free cash flow
76.93%4.85B
571.39%2.23B
-37.83%9.14B
-122.65%-743M
52.26%6.82B
-13.68%2.74B
-91.21%332M
52.23%14.71B
-14.18%3.28B
23.48%4.48B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 52.19%5.64B130.77%3.09B-31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B45.52%19.1B-13.05%4.43B16.78%5.6B
Net income from continuing operations 191.44%5.46B68.74%4.77B-97.40%377M-140.62%-1.23B46.06%4.75B-251.23%-5.97B-34.41%2.83B17.54%14.53B-21.08%3.02B-28.86%3.25B
Operating gains losses -132.39%-57M68.22%-143M-123.96%-340M-272.41%-100M-90.81%34M-37.81%176M-163.56%-450M173.14%1.42B114.32%58M154.33%370M
Depreciation and amortization 25.36%1.13B-0.71%984M-0.95%3.87B8.07%964M5.74%1.01B-3.73%903M-11.52%991M21.62%3.91B6.83%892M26.35%959M
Deferred tax 49.01%-181M81.59%-51M-21.11%-1.9B-203.26%-931M49.17%-336M-35.50%-355M18.05%-277M-938.50%-1.57B-293.08%-307M-66,000.00%-661M
Other non cash items -99.13%91M-25.73%739M804.23%11.76B240.15%449M-126.76%-99M1,488.26%10.42B595.80%995M-44.90%1.3B-56.86%132M116.37%370M
Change In working capital 38.14%-1.01B-17.02%-3.38B20.74%-2.21B141.50%144M727.76%2.18B-16.94%-1.64B-122.48%-2.89B27.53%-2.78B-671.11%-347M289.21%263M
-Change in receivables ---------78.26%-1.15B----------------68.32%-644M--------
-Change in inventory ---------406.83%-816M----------------76.11%-161M--------
-Change in payables and accrued expense --------3,843.90%1.62B-----------------71.13%41M--------
-Change in other current liabilities --------183.67%456M-----------------212.60%-545M--------
-Change in other working capital ---------57.09%-2.31B----------------16.21%-1.47B--------
Cash from discontinued investing activities 00
Operating cash flow 52.19%5.64B130.77%3.09B-31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B35.34%19.1B-11.95%4.43B16.78%5.6B
Investing cash flow
Cash flow from continuing investing activities 90.66%-1.07B41.67%-1.38B-183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B69.79%-4.96B85.49%-1.75B9.33%-962M
Capital expenditure reported 18.03%-791M14.50%-861M11.96%-3.86B13.93%-989M19.89%-902M14.53%-965M-2.34%-1.01B1.35%-4.39B4.88%-1.15B3.92%-1.13B
Net business purchase and sale --043.78%-746M-9,843.80%-12.03B--0--0---10.71B---1.33B99.06%-121M--0-12,200.00%-121M
Net investment purchase and sale -95.77%11M495.16%245M482.61%1.85B320.54%1.06B77.88%587M550.00%260M83.29%-62M-147.12%-483M-191.12%-482M197.30%330M
Net other investing changes -775.76%-289M-137.84%-14M-212.50%-36M82.05%-21M57.78%-19M-375.00%-33M-79.67%37M135.16%32M-10.38%-117M-4,400.00%-45M
Cash from discontinued investing activities
Investing cash flow 90.66%-1.07B41.67%-1.38B-183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B70.04%-4.96B85.49%-1.75B9.33%-962M
Financing cash flow
Cash flow from continuing financing activities -67.64%1.22B-37.00%-2.81B47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-394.45%-9.12B-129.84%-1.55B-18.82%-2.7B
Net issuance payments of debt -41.30%3.6B-75,000.00%-751M285.87%4.18B-200.00%-3M-94.50%-1.95B--6.13B99.92%-1M-238.01%-2.25B-100.01%-1M---1B
Net common stock issuance 25.74%-251M18.12%-122M---1.35B---393M---466M---338M---149M--0--0--0
Cash dividends paid -5.36%-1.99B-5.23%-1.95B-6.18%-7.45B-5.83%-1.85B-6.18%-1.86B-6.50%-1.89B-6.19%-1.85B-6.08%-7.01B-6.51%-1.75B-5.94%-1.75B
Proceeds from stock option exercised by employees -10.98%73M190.00%87M-67.45%125M-97.74%6M-30.00%7M-15.46%82M150.00%30M90.10%384M97.76%265M-41.18%10M
Net other financing activities 5.98%-220M3.70%-78M-36.67%-328M95.59%-3M-128.57%-10M-125.00%-234M21.36%-81M-102.75%-240M-106.06%-68M159.32%35M
Cash from discontinued financing activities 00
Financing cash flow -67.64%1.22B-37.00%-2.81B47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-451.68%-9.12B-129.84%-1.55B-18.82%-2.7B
Net cash flow
Beginning cash position -42.05%5.67B-45.91%6.91B56.40%12.77B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B0.17%8.17B12.27%11.28B13.01%9.75B
Current changes in cash 245.29%5.78B64.22%-1.1B-217.36%-5.89B-272.52%-1.95B60.68%3.11B-374.93%-3.98B-712.35%-3.07B3,312.24%5.02B162.29%1.13B32.56%1.94B
Effect of exchange rate changes 11.83%-82M-258.62%-138M105.61%23M-49.18%186M61.89%-157M69.90%-93M258.18%87M-208.27%-410M638.24%366M-795.65%-412M
End cash Position 99.11%11.37B-42.05%5.67B-45.91%6.91B-45.91%6.91B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B56.40%12.77B12.27%11.28B
Free cash flow 76.93%4.85B571.39%2.23B-37.83%9.14B-122.65%-743M52.26%6.82B-13.68%2.74B-91.21%332M52.23%14.71B-14.18%3.28B23.48%4.48B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --------------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Infectious Disease
Infectious Disease
Intraday+0.80%
Donald Trump
Donald Trump
Intraday-0.07%
Cancer Research
Cancer Research
Intraday-0.24%